Crestwood Advisors Group LLC Buys 74 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

by · The Cerbat Gem

Crestwood Advisors Group LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 476 shares of the biopharmaceutical company’s stock after acquiring an additional 74 shares during the period. Crestwood Advisors Group LLC’s holdings in Regeneron Pharmaceuticals were worth $500,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $26,000. Sachetta LLC raised its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the period. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $28,000. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the second quarter worth about $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.48% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

REGN has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Oppenheimer reduced their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Evercore ISI lowered their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,092.62.

Check Out Our Latest Report on REGN

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $816.65 on Thursday. The company has a market capitalization of $90.03 billion, a PE ratio of 20.21, a PEG ratio of 3.17 and a beta of 0.15. The business has a fifty day moving average price of $1,035.92 and a 200-day moving average price of $1,038.36. Regeneron Pharmaceuticals, Inc. has a 1-year low of $783.57 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read More